GENENTECH GDC4628g : Essai de phase 1, en escalade de dose, évaluant la tolérance d'un traitement par un inhibiteur de PI3 kinase (GDC-0941), du placlitaxel et du carboplatine, associé ou non à du bévacizumab, chez des patients ayant un cancer du poumon non à petites cellules. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase Ib, open-label, dose-escalation study of the safety and pharmacology of PI3-kinase inhibitor GDC-0941 in combination with paclitaxel and carboplatin with or without bevacizumab in patients wit...

• Country France
• organs Poumon, type non à petites cellules
• Specialty Thérapies Ciblées, Chimiothérapie

Study of the investigational drug MEHD7945A in comparison to the anticancer drug cetuximab in patients with head and neck cancer that progressed during or after platinum-based chemotherapy This is a phase II, open-label, randomized study of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or followin...

• Country None
• organs None
• Specialty None

A Study to Explore the Mechanism of Action of Ocrelizumab and B-cell Biology in Patients with Relapsing Multiple Sclerosis • To understand the impact of ocrelizumab treatment on neurofilament light (NfL) as a biomarker of neuronal damage in cerebrospinal fluid (CSF) • To assess the number of cluster of differentiation (C...

• Country None
• organs None
• Specialty None

A study to compare the effects of ipatasertib in combination with paclitaxel to placebo in combination with paclitaxel in patients with early stage triple negative breast cancer. ESTUDIO PARA COMPARAR LOS EFECTOS DE IPATASERTIB EN COMBINACIÓN CON PACLITAXEL O PLACEBO EN PACIENTES CON CÁNCER DE MAMA TRIPLENEGATIVO EN ESTADIO INICIAL - To estimate the efficacy of ipatasertib combined with paclitaxel compared with placebo combined with paclitaxel in patients with early stage TNBC, as measured by evaluation of pCR rate within the br...

• Country None
• organs None
• Specialty None

GENENTECH OAM4558g : Essai de phase 2 randomisé, en double aveugle, évaluant l'efficacité et la tolérance de l'erlotinib associé ou non à un anticorps anti-Met (MetMab), chez des patients ayant un cancer du poumons non à petites cellules. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and activity of MetMAb, a monovalent antagonist antibody to the receptor Met, administered to patients...

• Country France
• organs Poumon, type non à petites cellules
• Specialty Thérapies Ciblées

A clinical trial of MABT5102A for the treatment of Alzheimer's Disease Un ensayo clínico de MABT5102A para el tratamiento de la Enfermedad de Alzheimer To assess amyloid burden via 18F-florbetapir (18F-AV-45) positron emission tomography (florbetapir-PET) in patients with mild to moderate AD and to evaluate whether treatment with MABT5102A (a monoclo...

• Country None
• organs None
• Specialty None

GO27831 : Etude de phase 1, visant à évaluer la tolérance, la sécurité d’emploi et la pharmacocinétique de l’anticorps monoclonal MPDL3280A en monothérapie, chez des patients ayant une tumeur solide métastatique ou localement avancée ou une tumeur hématologique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer la tolérance et définir la dose optimale à administrer du MPDL3280A, chez des patients ayant une tumeur solide métastatique ou localement avancée ou une tumeur hé...

• Country France
• organs Tumeurs solides, Tout cancer hématologique
• Specialty Thérapies Ciblées

A study of quilizumab in patients with chronic spontaneous urticaria To study the efficacy and safety of quilizumab in patients with chronic spontaneous urticaria

• Country None
• organs None
• Specialty None